In preparation for what will surely be a heated issue, Novartis is working to condition payers and policymakers for the high cost of a forthcoming gene therapy, according to a STAT report.
The pharmaceutical giant says its new therapy to treat spinal muscular atrophy, Zolgensma, is cost effective at $4 million to $5 million for each patient
According to the report, the Institute for Clinical and Economic Review is preparing to release a draft report on the drug.
Click here to read the full report on STAT. (Paid subscription required)